Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Opiates
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Alcohol and drug treatment
Opioid-related deaths: current and emerging lessons
Opiates
Infectious diseases — Opiates
Opiates — Monitoring
Opiates — Public Health
Opiates — Treatment: medical/pharmacological
14:25
Why we have failed and where we can improve
The neglected public health problem of opioid use among offenders
14:25
10:50
Policy, practice and patient care
Depot medications for unmet treatment needs in opioid use disorder
10:50
to
12:20
Networking zone 2 (N2)
Michelle Lofwall
Opioid-related deaths in Europe and Australia
10:50
to
12:20
Main stage
Eilish Gilvarry
Towards a consensus approach to opioid substitution treatment outcomes and how they are monitored
10:50
to
12:20
Networking zone 1 (N1)
Lucas Wiessing
The European Mosaic: prescription drug misuse across borders
10:50
to
12:20
Central square 1 (C1)
Richard Dart
Monitoring trends and developments
10:50
to
12:20
Insights zone 1 (I1)
Larissa Maier
13:20
Nicotine harm reduction
13:20
to
14:50
Networking zone 4 (N4)
Ann McNeill
Treatment — challenges, determinants and responses
13:20
to
14:50
Networking zone 3 (N3)
Dominique Lopez
The challenges of monitoring new drugs
13:20
to
14:50
Insights zone 2 (I2)
Ana Gallegos
Lessons from the past applied to the future
Post-marketing prescription drug mosaic surveillance
13:20
to
14:50
Main stage
Richard Dart
Evidence to guide future practice and policy
Enhancing hepatitis C treatment outcomes among people who use drugs
13:20
to
14:50
Insights zone 1 (I1)
Catharina Matheï
Adrian Dunlop
Focus on prescription drugs I
13:20
to
14:50
Insights zone 3 (I3)
Volker Auwärter
Opioid-related deaths: learning from pharmacology, laboratory-based studies and physical assessments
13:20
to
14:50
Central square 1 (C1)
Sir John Strang
Treatment adherence
13:20
to
14:50
Insights zone 4 (I4)
Marta Torrens Melich
15:00
Improving youth OUD treatment through family engagement and assertive outreach
15:00
to
16:30
Futures zone 3 (F3)
Marc Fishman
Ann Bruner
Improving responses to opioid-related harm
15:00
to
16:30
Central square 3 (C3)
Steve Gust
Therapeutic horizons I
15:00
to
16:30
Networking zone 1 (N1)
Wouter Vanderplasschen
Take-home naloxone — its role in preventing opioid-related deaths in Europe
15:00
to
16:30
Insights zone 3 (I3)
Dagmar Hedrich
Sir John Strang
16:50
Extending the evidence-base of opioid substitution treatment
16:50
to
18:20
Insights zone 4 (I4)
John Marsden
New methods
16:50
to
18:20
Central square 2 (C2)
André Noor
Striving towards the future elimination of Hep C among people who use drugs
16:50
to
18:20
Futures zone 1 (F1)
Eberhard Schatz
Perrine Roux
18:30
Innovative approaches for assessing or impacting demand for substances
18:30
to
19:30
Central square 1 (C1)
Anne Line Bretteville-Jensen
Opioids — current and emerging lessons
18:30
to
19:30
Networking zone 4 (N4)
Roumen Sedefov
10:45
Treatment — improving standards and outcomes
10:45
to
12:15
Networking zone 3 (N3)
Gerhard Bühringer
Opioid-related deaths: learning from epidemiological studies
10:45
to
12:15
Insights zone 3 (I3)
Sarah Welch
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
10:50
Oral presentation
European policy issues that affect OUD treatment access
10:50
to
11:05
Networking zone 2 (N2)
Gabriele Fischer
11:00
Oral presentation
Drug deaths in Scotland: inevitable or preventable?
11:00
to
11:15
Main stage
Roy Robertson
11:05
Oral presentation
Overview of potential benefits of depot therapies, reviewing several newer buprenorphine depot formulations including the 6-month implants
11:05
to
11:30
Networking zone 2 (N2)
Michelle Lofwall
11:15
Oral presentation
Cause-specific excess mortality in people who use opioids illicitly: systematic review and meta-analysis
11:15
to
11:30
Main stage
Sarah Larney
11:30
Oral presentation
Open-label safety study conducted in Europe, Australia and the US
11:30
to
11:55
Networking zone 2 (N2)
Genie Bailey
Oral presentation
Prevention of drug related mortality: the role of opioid agonist treatment
11:30
to
12:00
Main stage
Matthew Hickman
Louisa Degenhardt
11:55
Oral presentation
The implications for European patients, practice and policy
11:55
to
12:20
Networking zone 2 (N2)
Gabriele Fischer
Sharon L. Walsh
12:00
Oral presentation
Discussant
12:00
to
12:20
Main stage
Edward Nunes
13:30